NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference
(firmenpresse) - AMES, IA -- (Marketwired) -- 12/05/13 -- NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, announced today that Charles J. Link, Jr., M.D., NewLink's Founder and Chief Executive Officer, is scheduled to present at the Oppenheimer 24th Annual Healthcare Conference in New York, on Tuesday, December 11, 2013 at 1:35 p.m. ET.
NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for patients with cancer. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. For more information please visit . Patient information is available at .
Gordon Link
Chief Financial Officer
515-598-2925
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 05.12.2013 - 12:00 Uhr
Sprache: Deutsch
News-ID 322512
Anzahl Zeichen: 0
contact information:
Town:
AMES, IA
Kategorie:
Hospitals, Facilities and Providers
Diese Pressemitteilung wurde bisher 235 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"NewLink Genetics to Present at the Oppenheimer 24th Annual Healthcare Conference"
steht unter der journalistisch-redaktionellen Verantwortung von
NewLink Genetics Corporation (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
